EFSA grants NuLiv Science’s AstraGin Novel Food status

September 15, 2020

NuLiv Science received Novel Food status approval from the European Food Safety Authority (EFSA) for its flagship ingredient, AstraGin.

NuLiv Science (Brea, CA) received Novel Food status approval from the European Food Safety Authority (EFSA) for its flagship ingredient, AstraGin. A proprietary extract from Panax notoginseng and Astragalus membranaceus, AstraGin supports the absorption and bioavailability of key nutrients such as amino acids, omegas, and folate, among others in the intestinal lumen. 

"It's been a long, insightful journey and we're very grateful to all the people who've been part of the process, from our science and production staff to Nutraveris, our consulting partner, to the wisdom of EFSA,” said Richard Wang, president at NuLiv Science, in a press release. “We're excited to offer AstraGin to the European market.” 

In 2012, NuLiv Science earned GRAS (generally recognized as safe) status for AstraGin along with a Natural Product Number (NPN) granted by Health Canada in 2017, which catapulted the ingredient into the Canadian dietary supplement market. 

“This is an exciting time for the AstraGin brand since we’ve been poised and ready to enter the European market,” Josh Beaty, marketing director, said in a press release. “Over the past few years, we’ve been developing relationships with a number of key players in the industry and now we can help those brands build their dream products they’ve envisioned. We look forward to the expansion of AstraGin across Europe.”